When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological ... and 45,909 with Parkinson’s ...
The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...
A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...
People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study examined the ...
Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...
Dementia is a progressive condition that affects brain function, leading to a decline in cognitive skills such as memory and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback